ASH Clinical News December 2014 | Page 79
Detect Blood Cancer Relapse
Early and With Confidence
Accurately diagnose and track minimal residual disease (MRD)
at a molecular level with the clonoSEQ™ Test, performed in a
CLIA-certified lab, for patients with lymphoid malignancies.
Why the clonoSEQ Test?
Demonstrated accuracy and sensitivity: uses proprietary PCR bias control
methodology to deliver accurate, quantifiable T- and B-cell receptor
sequencing results
Validated clinical use: can be used to monitor MRD for patients with ALL,
CLL, CTCL, DLBCL, MM, NHL
Sample flexibility: provides results from DNA, blood, bone marrow, and
formalin-fixed, paraffin-embedded tissue
Ease of use: easy-to-read clinical reports provided within 7 days
Learn more at adaptivebiotech.com or by calling 855-466-8667
1551 Eastlake Avenue East, Suite 200 • Seattle, WA 98102
P: 855.466.8667
W: adaptivebiotech.com
Copyright © 2014 Adaptive Biotechnologies Corp.
All rights reserved. 11/2014 MRK-20005 AA